New World Angels Invests $697K in Aegle Therapeutics' Clinical Trials
BOCA RATON, FL (March 4, 2025) – New World Angels (“NWA”) a leading Florida-based structured angel capital investment organization, announced today that it had completed the purchase of $697,500 of Aegle Therapeutics’ convertible notes. Aegle is a leading clinical-stage biopharmaceutical company developing novel extracellular vesicle (EV) therapies for the treatment of severe and rare inflammatory and immuno-dermatological diseases. Aegle is currently enrolling subjects in a multi-site clinical trial for the treatment of Dystrophic Epidermolysis Bullosa (DEB), a rare pediatric disease. Additionally, Aegle has compelling safety and efficacy data from a grant-supported proof-of-concept deep second-degree burn trial. In December 2024, Aegle launched a $3MM Convertible Note Series to fund the completion of the DEB trial as well as other operations through 2025. “Support from key investors, including NWA, has been critical to Aegle’s advancement into the clinic and to the generation of compelling, early patient data,” said Shelley Hartman, Chief Executive Officer.
Previously, NWA had invested approximately $2.4MM into Aegle's Preferred Stock offerings and owns about 10% of the fully diluted stock of Aegle. Dr. David Schimel, an NWA and Aegle director and co-lead of NWA’s healthcare practice, noted, “We are excited to continue our support of Aegle and its pursuit of treatments for a wide range of dermatological challenges by using EVs derived from Mesenchymal stem cells (MSCs) to help a patient’s body heal itself. We are greatly encouraged by the initial patient results in the burn and DEB trials and, therefore, have taken the opportunity to increase our ownership percentage going forward.”
About New World Angels:
New World Angels (NWA) is a group of 100+ accredited, private investors, operators, and entrepreneurs dedicated to providing equity capital and guidance to early-stage entrepreneurial companies, especially those with a strong presence in Florida. Members of NWA have extensive experience in founding, building, and managing companies in various industries. NWA members are involved in the entrepreneurial communities from Miami to Melbourne on Florida’s east coast and from Naples to Orlando on Florida’s west coast. NWA has invested over $30 million in innovative start-ups. In addition to providing funding, NWA members make their expertise and resource networks available to portfolio companies to facilitate a company’s growth.
About Aegle Therapeutics Corp.:
Aegle Therapeutics is a clinical-stage biopharmaceutical company developing novel extracellular vesicle therapies for treating immune and inflammatory-based dermatological disorders. Aegle is a first-in-class, Massachussetts and Miami-based biotechnology company isolating extracellular vesicles (“EVs”), including exosomes, secreted by allogeneic bone marrow-derived mesenchymal stem cells as therapy.
Media Contact:
Jessica Miley
Managing Director, New World Angels
(617) 504-1864
Jessica@newworldangels.com